Comparable stake leader
Udi Gilboa
SEC ownership of Nasus Pharma Ltd
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0002029039.
Disclosed value leader
Udi Gilboa
Comparable rows
15/15
Latest evidence
22 Apr 2026
- Public ticker
- NSRX on NYSE
- Parsed ownership sources
-
3/4/5, 13D/G, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Udi Gilboa
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
15 of 15
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Udi Gilboa
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
22 Apr 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0002029039
- Issuer location
- Tel Aviv Yafo, Israel
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Nasus Pharma Ltd (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Udi Gilboa
Disclosed value leader
Udi Gilboa
Comparable rows
15/15
Latest evidence
22 Apr 2026
3/4/5
13D/G
13F
Lead comparable stake: 21%
13D/G row: Udi Gilboa
Showing 1-8 of 15 holder rows.
Quick read
Udi Gilboa leads the comparable SEC ownership view at 21%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Udi Gilboa's linked filing trail.
Comparable ownership
Top 5
Udi Gilboa
21%
Dalia Megiddo
21%
Ronnie Hershman
15%
BALYASNY ASSET MANAGEMENT L.P.
10%
Capital Point Ltd.
6.4%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Udi Gilboa |
3/4/5
13D/G
Founder & Executive Chairman
|
21%
from 13D/G
|
$17,609,724
1,924,476 shares
|
— | 18 Mar 2026 |
| Dalia Megiddo |
3/4/5
13D/G
Chief Development Officer, Director, Founder · Dr. Dalia Megiddo
|
21%
from 13D/G
|
$17,331,479
1,894,068 shares
|
— | 18 Mar 2026 |
| Ronnie Hershman |
3/4/5
13D/G
Director · Dr. Ronnie Hershman
|
15%
from 13D/G
|
$12,247,471
1,338,463 shares
|
— | 18 Mar 2026 |
| BALYASNY ASSET MANAGEMENT L.P. |
13D/G
13F
Company
|
10%
|
$2,714,191
1,169,910 shares
|
$0 | 31 Mar 2026 |
| Capital Point Ltd. |
13D/G
|
6.4%
|
—
575,129 shares
|
$0 | 14 Aug 2025 |
| Funicular Funds, LP |
13D/G
|
5.2%
|
$3,309,730
612,913 shares
|
$0 | 31 Mar 2026 |
| Dan Benjamin Teleman |
3/4/5
Chief Executive Officer, Director
|
1.3%
|
$590,286
156,991 shares
|
+$41,504 | 22 Apr 2026 |
| Cable Car Capital, LP |
13F
Company
|
5.1%
|
$1,336,436
601,998 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to buying over the last 12 months. Net value: +$41,504.
Buys
$41,504
Insiders: 1
Sells
$0
Insiders: 0
Net
+$41,504
Shares: +17,900
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 17,900
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 17,900 | 0 | $41,504 | $0 | +$41,504 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-8 of 8 reporting-owner rows connected to Nasus Pharma Ltd. Open a relationship link for the CIK-to-CIK filing trail.
Rows
8
Largest Forms 3/4/5 holder
Udi Gilboa
Net 12M change
+$41,504
Latest report
22 Apr 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Udi Gilboa | Founder & Executive Chairman | $17,609,724 | Mixed | 18 Mar 2026 | ||
| Dalia Megiddo | Chief Development Officer, Director, Founder | $17,331,479 | Mixed | 18 Mar 2026 | ||
| Ronnie Hershman | Director | $12,247,471 | Mixed | 18 Mar 2026 | ||
| Dan Benjamin Teleman | Chief Executive Officer, Director | $590,286 | +$41,504 | +7.6% | Filing P/S | 22 Apr 2026 |
| Silberman David | Director | Mixed | 18 Mar 2026 | |||
| Eyal Rubin | Chief Financial Officer, EVP | Mixed | 18 Mar 2026 | |||
| Sharon Shacham | Director | Mixed | 18 Mar 2026 | |||
| Israel Isaac | Director | Mixed | 18 Mar 2026 |
Recent insider transactions for Nasus Pharma Ltd
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Dan Benjamin Teleman | NSRX | Ordinary Shares | Purchase | 1.88% | $10,904 | $3.76 | 2,900 | 156,991 | 22 Apr 2026 | Direct |
| Dan Benjamin Teleman | NSRX | Ordinary Shares | Purchase | 240.2% | $30,600 | $2.04 | 15,000 | 21,246 | 31 Mar 2026 | Direct |
* marks a reported price that did not pass the local price check.